Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Adil Daud, MD
UCSF Medical Center at Mount Zion
Principal Investigator - Kevin B Kim, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucsf Medical Center at Mount Zion
South San Francisco, California, United States
- University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
- Georgetown-Lombardi Comprehensive Cancer Ctr
Washington D.C., District of Columbia, United States
- the University of Texas, Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2013
- Primary completion
- 31 Mar 2015
- Completion
- 31 Mar 2016
- Last update posted
- 4 Sept 2014
- Registered enrollment
- 100
- Registry id
- NCT01841463
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.